GeoVax Labs (GOVX) 10-Q 14 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 04, 2017
Document Information [Line Items]
Entity Registrant Name	GeoVax Labs, Inc.
Entity Central Index Key	832,489
Trading Symbol	govx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		66,913,900
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Cash and cash equivalents	$ 822,597	$ 454,030
Grant funds receivable	78,772	28,074
Prepaid expenses and other current assets	32,248	62,275
Total current assets	933,617	544,379
Property and equipment, net	45,382	54,828
Deposits	11,010	11,010
Total assets	990,009	610,217
Current liabilities:
Accounts payable	151,954	75,607
Accrued expenses (Note 6)	499,638	294,240
Total current liabilities	651,592	369,847
Commitments (Note 7)
Stockholders’ equity:
Common stock, $.001 par value: Authorized shares - 300,000,000 Issued and outstanding shares – 62,913,900 and 55,235,233 at June 30, 2017 and December 31, 2016, respectively	62,914	55,235
Additional paid-in capital	35,109,553	34,914,963
Accumulated deficit	(36,811,850)	(35,746,628)
Total stockholders’ equity	338,417	240,370
Total liabilities and stockholders’ equity	990,009	610,217
Series B Convertible Preferred Stock [Member]
Stockholders’ equity:
Convertible Preferred Stock	76,095	76,095
Series C Convertible Preferred Stock [Member]
Stockholders’ equity:
Convertible Preferred Stock	921,705	940,705
Series D Convertible Preferred Stock [Member]
Stockholders’ equity:
Convertible Preferred Stock	$ 980,000

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares issued (in shares)	62,913,900	55,235,233
Common stock, shares outstanding (in shares)	62,913,900	55,235,233
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Series B Convertible Preferred Stock [Member]
Preferred stock, shares issued (in shares)	100	100
Preferred stock, shares outstanding (in shares)	100	100
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Series C Convertible Preferred Stock [Member]
Preferred stock, shares issued (in shares)	2,810	2,868
Preferred stock, shares outstanding (in shares)	2,810	2,868
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Series D Convertible Preferred Stock [Member]
Preferred stock, shares issued (in shares)	1,000	0
Preferred stock, shares outstanding (in shares)	1,000	0
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Grant and collaboration revenue	$ 352,137	$ 166,280	$ 647,872	$ 213,880
Operating expenses:
Research and development	518,098	397,576	1,069,893	835,580
General and administrative	352,191	344,818	644,858	1,251,323
Total operating expenses	870,289	742,394	1,714,751	2,086,903
Loss from operations	(518,152)	(576,114)	(1,066,879)	(1,873,023)
Other income:
Interest income	1,271	279	1,657	909
Net loss	$ (516,881)	$ (575,835)	$ (1,065,222)	$ (1,872,114)
Basic and diluted:
Loss per common share (in dollars per share)	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.05)
Weighted averages shares outstanding (in shares)	59,791,475	37,425,291	57,583,491	36,012,458

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (1,065,222)	$ (1,872,114)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	13,796	14,390
Stock-based compensation expense	29,102	497,171
Changes in assets and liabilities:
Grant funds receivable	(50,698)	119,978
Prepaid expenses and other current assets	30,027	12,954
Accounts payable and accrued expenses	281,745	53,205
Total adjustments	303,972	697,698
Net cash used in operating activities	(761,250)	(1,174,416)
Cash flows from investing activities:
Purchase of property and equipment	(4,350)
Net cash used in investing activities	(4,350)
Cash flows from financing activities:
Net proceeds from sale of preferred stock	980,000
Net proceeds from sale of common stock	154,167	329,198
Net cash provided by financing activities	1,134,167	329,198
Net increase (decrease) in cash and cash equivalents	368,567	(845,218)
Cash and cash equivalents at beginning of period	454,030	1,060,348
Cash and cash equivalents at end of period	$ 822,597	$ 215,130

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - Series C Convertible Preferred Stock [Member] - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Convertible preferred stock (in shares)	58	132
Conversion of stock, shares issued (in shares)	3,862,000	1,400,000

Note 1 - Description of Busines

Note 1 - Description of Business	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Nature of Operations [Text Block]	1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines using our novel vaccine platform. Our current development programs are focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. We believe our technology and vaccine development expertise are well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline. Our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of Presentation The accompanying condensed consolidated financial statements at June 30, 2017 three six June 30, 2017 2016 not 10 December 31, 2016. not Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We believe that our existing cash resources and government funding commitments will be sufficient to continue our planned operations through the end of 2017. not may not

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Significant Accounting Policies and Recent Accounting Pronouncements We disclosed in Note 2 10 December 31, 2016 no 10 In March 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting 2016 09” 718, 2016 09 2016 09 January 1, 2017; no In May 2017, 2017 09, Scope of Modification Accounting 2017 09” 718, 2017 09 1 2 718 2017 09 January 1, 2018. 2017 09 In July 2017, 2017 11, (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception 2017 11” 260, 480, 815. 2017 11 2017 11 January 1, 2019. 2017 11 no six June 30, 2017, 10 December 31, 2016,

Note 4 - Basic and Diluted Loss

Note 4 - Basic and Diluted Loss Per Common Share	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic and Diluted Loss Per Common Share Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares and potentially dilutive common share equivalents outstanding during the period. Potentially dilutive common share equivalents consist of convertible preferred stock, stock options and stock purchase warrants. Common share equivalents which potentially could dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, as the effect would be anti-dilutive, totaled approximately 285.5 83.8 June 30, 2017 2016,

Note 5 - Property and Equipment

Note 5 - Property and Equipment	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of June 30, 2017 December 31, 2016: June 30, 2017 December 31, 2016 Laboratory equipment $ 530,306 $ 525,956 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 674,596 670,246 Accumulated depreciation and amortization (629,214 ) (615,418 ) Property and equipment, net $ 45,382 $ 54,828

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Expenses Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of June 30, 2017 December 31, 2016: June 30, 2017 December 31, 2016 Accrued salaries $ 351,268 $ 201,170 Accrued directors’ fees 133,370 78,070 Other 15,000 15,000 Total accrued expenses $ 499,638 $ 294,240

Note 7 - Commitments

Note 7 - Commitments	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Commitments Disclosure [Text Block]	7. Commitments Lease Agreement We lease approximately 8,400 December 31, 2018, 12 June 30, 2017, $232,541, $75,996 2017 $156,545 2018. Other Commitments In the normal course of business, we may June 30, 2017, $158,000 2017. 10

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Stockholders’ Equity Series B Convertible Preferred Stock As of June 30, 2017, 100 may $0.35, 285,714 During the six June 30, 2017, no Series C Convertible Preferred Stock As of June 30, 2017, 2,810 may $0.015, 187,349,733 In May 2017, $0.05 $0.015 six June 30, 2017, 3,862,000 58 Series D Convertible Preferred Stock In May 2017, 1,000 $1,000 $1.0 $980,000 . Each share of Series D Preferred Stock is entitled to a liquidation preference equal to the initial purchase price, has no not $0.015 The Series D Preferred Shares contains price adjustment provisions, which may, We assessed the Series D Preferred Stock under ASC Topic 480, Distinguishing Liabilities from Equity 480” 815, Derivatives and Hedging 815” 470, Debt 470” 815 not 815. Common Stock Transactions During May June 2017, 3,862,000 58 During March 2017, 983,334 $49,167. During April 2017, 2,500,000 $100,000. During May 2017, 333,333 $5,000. Stock Options The following table presents a summary of our stock option transactions during the six June 30, 2017: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 3,499,475 $ 1.21 Granted -- -- Exercised -- -- Forfeited or expired (115,200 ) 17.75 Outstanding at June 30, 2017 3,384,275 $ 0.64 Exercisable at June 30, 2017 1,135,494 $ 1.77 Stock Purchase Warrants The following table presents a summary of stock purchase warrant transactions during the six June 30, 2017: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 32,751,578 $ 0.07 Granted -- -- Exercised (3,816,667 ) 0.02 Forfeited or expired (1,112,001 ) 0.57 Outstanding at June 30, 2017 27,822,910 $ 0.02 Exercisable at June 30, 2017 27,822,910 $ 0.02 Stock-Based Compensation Expense Stock-based compensation expense related to our stock option plans was $14,522 $29,102 three six June 30, 2017, $13,686 $27,372 three six June 30, 2016, June 30, 2017, $102,882 2.1

Note 9 - Income Taxes

Note 9 - Income Taxes	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9. Income Taxes Because of our historically significant net operating losses, we have not 382

Note 10 - Grants and Collaborat

Note 10 - Grants and Collaboration Revenue	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Government Grants and Contracts [Text Block]	10. Grants and Collaboration Revenue Government Grants and Contracts We receive payments from government entities under our grants and contracts with the National Institute of Allergy and Infectious Diseases in support of our vaccine research and development efforts. We record revenue associated with government grants and contracts as the reimbursable costs are incurred. During the three six June 30, 2017, $257,137 $552,872, $166,280 213,880, 2016. June 30, 2017, $910,774 Collaboration Revenue In March 2017, 1 second 2017 $95,000 three six June 30, 2017.

Note 11 - Subsequent Events

Note 11 - Subsequent Events	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	11. Subsequent Events During July 2017, 4,000,000 60 At a special meeting of our stockholders held on August 4, 2017, 300,000,000 600,000,000

Note 5 - Property and Equipme18

Note 5 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, 2017 December 31, 2016 Laboratory equipment $ 530,306 $ 525,956 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 674,596 670,246 Accumulated depreciation and amortization (629,214 ) (615,418 ) Property and equipment, net $ 45,382 $ 54,828

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2017 December 31, 2016 Accrued salaries $ 351,268 $ 201,170 Accrued directors’ fees 133,370 78,070 Other 15,000 15,000 Total accrued expenses $ 499,638 $ 294,240

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Share-based Compensation, Activity [Table Text Block]	Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 3,499,475 $ 1.21 Granted -- -- Exercised -- -- Forfeited or expired (115,200 ) 17.75 Outstanding at June 30, 2017 3,384,275 $ 0.64 Exercisable at June 30, 2017 1,135,494 $ 1.77
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 32,751,578 $ 0.07 Granted -- -- Exercised (3,816,667 ) 0.02 Forfeited or expired (1,112,001 ) 0.57 Outstanding at June 30, 2017 27,822,910 $ 0.02 Exercisable at June 30, 2017 27,822,910 $ 0.02

Note 4 - Basic and Diluted Lo21

Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares shares in Millions	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	285.5	83.8

Note 5 - Property and Equipme22

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Property and equipment, gross	$ 674,596	$ 670,246
Accumulated depreciation and amortization	(629,214)	(615,418)
Property and equipment, net	45,382	54,828
Laboratory Equipment [Member]
Property and equipment, gross	530,306	525,956
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 28,685	$ 28,685

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Accrued salaries	$ 351,268	$ 201,170
Accrued directors’ fees	133,370	78,070
Other	15,000	15,000
Total accrued expenses	$ 499,638	$ 294,240

Note 7 - Commitments (Details T

Note 7 - Commitments (Details Textual)	6 Months Ended
	Jun. 30, 2017USD ($)ft²
Area of Real Estate Property | ft²	8,400
Lessee, Operating Lease, Renewal Term	12 years
Operating Leases, Future Minimum Payments Due	$ 232,541
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year	75,996
Operating Leases, Future Minimum Payments, Due in Two Years	156,545
Unrecorded Unconditional Purchase Obligation	$ 158,000

Note 8 - Stockholders' Equity25

Note 8 - Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended			2 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2017	Apr. 30, 2017	Mar. 31, 2017	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	May 01, 2017	Dec. 31, 2016
Preferred Stock, Par or Stated Value Per Share				$ 0.01	$ 0.01		$ 0.01			$ 0.01
Proceeds from Issuance of Convertible Preferred Stock							$ 980,000
Stock Issued During Period, Shares, Warrants Exercised	333,333	2,500,000	983,334
Proceeds from Warrant Exercises	$ 5,000	$ 100,000	$ 49,167
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized				$ 102,882	$ 102,882		$ 102,882
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							2 years 36 days
2006 Equity Incentive Plan [Member]
Allocated Share-based Compensation Expense					$ 14,522	$ 13,686	$ 29,102	$ 27,372
Conversion of Series C Preferred Stock Into Common Stock [Member]
Stock Issued During Period, Shares, New Issues				3,862,000			3,862,000
Conversion of Stock, Shares Converted				58			58
Series B Convertible Preferred Stock [Member]
Convertible Preferred Stock, Total Conversion Shares				285,714	285,714		285,714
Conversion of Stock, Shares Converted							0
Preferred Stock, Shares Outstanding				100	100		100			100
Preferred Stock, Par or Stated Value Per Share				$ 1,000	$ 1,000		$ 1,000			$ 1,000
Convertible Preferred Stock, Conversion Price1				$ 0.35	$ 0.35		$ 0.35
Series C Convertible Preferred Stock [Member]
Convertible Preferred Stock, Total Conversion Shares				187,349,733	187,349,733		187,349,733
Conversion of Stock, Shares Converted							58	132
Preferred Stock, Shares Outstanding				2,810	2,810		2,810			2,868
Preferred Stock, Par or Stated Value Per Share				$ 1,000	$ 1,000		$ 1,000			$ 1,000
Convertible Preferred Stock, Conversion Price1		$ 0.05		$ 0.015	$ 0.015		$ 0.015		$ 0.015
Series D Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues	1,000
Preferred Stock, Shares Outstanding				1,000	1,000		1,000			0
Preferred Stock, Par or Stated Value Per Share	$ 1,000			$ 1,000	$ 1,000		$ 1,000			$ 1,000
Proceeds from Issuance of Convertible Preferred Stock, Gross	$ 1,000,000
Proceeds from Issuance of Convertible Preferred Stock	$ 980,000
Convertible Preferred Stock, Conversion Price1	$ 0.015

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Activity of Stock Option Plan (Details)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Outstanding, options (in shares) | shares	3,499,475
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 1.21
Granted, options (in shares) | shares
Granted, weighted average exercise price, options (in dollars per share) | $ / shares
Forfeited or expired, options (in shares) | shares	(115,200)
Forfeited or expired, weighted average exercise price, options (in dollars per share) | $ / shares	$ 17.75
Outstanding, options (in shares) | shares	3,384,275
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.64
Exercisable, options (in shares) | shares	1,135,494
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 1.77

Note 8 - Stockholders' Equity27

Note 8 - Stockholders' Equity - Outstanding Stock Purchase Warrants (Details)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Outstanding, shares (in shares) | shares	32,751,578
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 0.07
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 0.02
Exercisable, shares (in shares) | shares	27,822,910
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 0.02
Exercised, shares (in shares) | shares	(3,816,667)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 0.02
Forfeited or expired, shares (in shares) | shares	(1,112,001)
Forfeited or expired, weighted average exercise price (in dollars per share) | $ / shares	$ 0.57
Outstanding, shares (in shares) | shares	27,822,910

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) $ in Thousands	192 Months Ended
	Jun. 30, 2017USD ($)
Income Tax Expense (Benefit)	$ 0

Note 10 - Grants and Collabor29

Note 10 - Grants and Collaboration Revenue (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue from Grants	$ 352,137	$ 166,280	$ 647,872	$ 213,880
Revenue from Collaboration	95,000		95,000
NIH Grants [Member]
Revenue from Grants	257,137	$ 166,280	552,872	$ 213,880
Unused Grant Funds	$ 910,774		$ 910,774

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - shares	1 Months Ended	2 Months Ended	6 Months Ended
	Jul. 31, 2017	Jun. 30, 2017	Jun. 30, 2017	Aug. 04, 2017	Dec. 31, 2016
Common Stock, Shares Authorized		300,000,000	300,000,000		300,000,000
Conversion of Series C Preferred Stock Into Common Stock [Member]
Stock Issued During Period, Shares, New Issues		3,862,000	3,862,000
Conversion of Stock, Shares Converted		58	58
Subsequent Event [Member]
Common Stock, Shares Authorized				600,000,000
Subsequent Event [Member] | Conversion of Series C Preferred Stock Into Common Stock [Member]
Stock Issued During Period, Shares, New Issues	4,000,000
Conversion of Stock, Shares Converted	60